Weiwei Tan - Concepedia

Author

Weiwei Tan

Pfizer (United States)ORCID

Also Known As

Hong, Tan Weng, W Tan, W. Tan, Wei-Wei Tan, Wei-wei Tan, WeiWei Tan, Weiwei Tan

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Massachusetts General Hospital Dana-Farber Cancer Institute Peter MacCallum Cancer Centre Pfizer (Italy)

About

Weiwei Tan is an author at Pfizer (United States) specializing in medicine, pharmacology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	904
2	Cell Biology	3	3	616
3	Nephrology	1	1	23
4	Nutrition	1	1	44
5	Obstetrics	1	1	54

Weiwei Tan

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, New England Journal of Medicine	2010	4.5K
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, New England Journal of Medicine	2014	2K
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya, Journal of Clinical Oncology	2011	587
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Sai‐Hong Ignatius Ou, Eunice L. Kwak, Christina T. Siwak-Tapp, Journal of Thoracic Oncology Tumor BiologyOncologyMedicineDual Mesenchymal-epithelial TransitionPathology	2011	433
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers Patricia LoRusso, Smitha Krishnamurthi, John J. Rinehart, Clinical Cancer Research	2010	247
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Alice T. Shaw, D. Ross Camidge, Jeffrey A. Engelman, Journal of Clinical Oncology PathologyPharmacotherapyCancer BiologyTumor BiologyPre-clinical Pharmacology	2012	129
Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model Shinji Yamazaki, Judith Skaptason, David Romero, Drug Metabolism and Disposition	2010	61
Complex renal cysts associated with crizotinib treatment Patrick Schnell, Cynthia Huang Bartlett, Benjamin Solomon, Cancer Medicine	2015	60
Metabolism, excretion and pharmacokinetics of [<sup>14</sup>C]crizotinib following oral administration to healthy subjects Theodore R. Johnson, Weiwei Tan, Lance Goulet, Xenobiotica	2014	56
Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways Weiwei Tan, Meihong Pan, Hui Liu, OncoTargets and Therapy Chemoprevention StrategyLipid PeroxidationGynecologyTumor BiologyOxidative Stress	2017	54

Page 1